Kenichi Harano

20PUBLICATIONS
201CO-AUTHORS
Immunogenetics (incl. genetic immunology)Molecular targetsPredictive and prognostic markersGeriatrics and gerontologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Oct 07, 2026
Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single-Center Japanese Retrospective Cohort Study.

|Sep 26, 2026
Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: 2025 edition by the Japan Society of Gynecologic Oncology.

|Sep 17, 2026
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

|Aug 07, 2026
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

|Jul 30, 2026
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study.

|Jul 25, 2026
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis.

Pageof 4

Frequent Collaborators

11 joint publications

Kazuhiro Takehara

9 joint publications

Aikou Okamoto

6 joint publications

Hidemichi Watari

6 joint publications

Daisuke Aoki